Evotec SE (OTCPK:EVOTF) will regain
global development and commercialisation rights to the iPSC-based
program for the treatment of diabetes developed under collaboration
agreement with Sanofi.
Evotec produces human beta cells in islet-like clusters from a GMP-compliant iPS cell line in a scalable bioreactor format.
The beta cell program has already achieved
pre-clinical data demonstrating that they are functionally equivalent to
primary human islets in their ability to normalise blood glucose levels
in in vivo models over several months.
Evotec will continue the development of the beta
cell program on its own within its EVT Innovate initiative “QRbeta
Therapeutics”.
https://seekingalpha.com/news/3563091-evotec-regains-global-rights-to-beta-cell-replacement-therapy
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.